Trial size COL3A1 antibodies available in the Antibody Validation Project

Posted by M.Popov on 12th Nov 2020

Trial size COL3A1 antibodies available in the Antibody Validation Project

Trial size COL3A1 antibodies available in the Antibody Validation Project

Introduction:

Collagen type III alpha 1 chain, is the protein produced by the COL3A1 gene and responsible for regulation of cortical development, inhibiting neuron migration and activating the RhoA pathway. It is mainly expressed in the cervix and uterine and is believed to be secreted to the extracellular matrix on cell level. Despite its key functions in the human body, COL3A1 can bring many serious conditions if it is overexpressed or mutations occur, for example Ehlers-Danlos syndrome type 4 , epilepsy, several cancers and aortic aneurysms are some of the diseases related to the mutation of this gene. Apart from that, it can be used as a prognostic marker in unfavourable renal cancer and we provide a number of trial sized antibodies, which are suitable for COL3A1 research purposes, and to help you make the right decision and find the best suited antibody for you, please find the answers to some of the key topics regarding COL3A1 that we have provided in the links below.

What is COL3A1?

This gene encodes the pro-alpha1 chains of type III collagen, a fibrillar collagen that is found in extensible connective tissues such as skin, lung, uterus, intestine and the vascular system, frequently in association with type I collagen. It is involved in regulation of cortical development, and is the major ligand of ADGRG1 in the developing brain and binding to ADGRG1 inhibits neuronal migration and activates the RhoA pathway by coupling ADGRG1 to GNA13 and possibly GNA12.

Where is COL3A1 found?

COL3A1 is localised in the endoplasmic reticulum and is believed to be secreted to the extracellular matrix. Furthermore, it is absent in immune cells and is highly expressed in the cervix, uterine and endometrium.

What role does COL3A1 play in disease?

Mutations in the COL3A1 gene are associated with Ehlers-Danlos syndrome type 4 and with arterial and aortic aneurysms. Furthermore, visual epilepsy also known as "seizures" and Acrogeria, Gottron type diagnosed by premature aging with thin fragile skin mainly on the hands and feet are closely related to mutations of this gene.

COL3A1 antibodies in the Antibody Validation project

St John's Laboratory offers a variety of trial size primary antibodies which target COL3A1 , which are available to try through the Antibody Validation Project. Below we highlight those which have already been reviewed, as well as others which are available to try.

Customer reviewed COL3A1 antibodies

ModelNameHostClonalityRatingApplication Tested
STJ92388Anti-COL3A1 antibody RabbitPolyclonal5ICC
STJ92388Anti-COL3A1 antibodyRabbitPolyclonal5IHC

Other COL3A1 antibodies available in the Antibody Validation Project

ModelNameHostClonalityRecommended Applications
STJ150349Rat COL3A1 ELISA Kit  ELISA
STJ90049Anti-Cleaved-COL3A1 (G1221) antibodyRabbitPolyclonalELISA,WB
STJ92388Anti-COL3A1 antibodyRabbitPolyclonalELISA,FC,IF,IHC
STJ97025Anti-Collagen III antibodyMouseMonoclonalWB
ModelNameHostClonalityRecommended Applications
STJ23192Anti-COL3A1 AntibodyRabbitPolyclonalWB

How does the Antibody Validation Project work?

In order to help our customers with their choice of antibody with low risk, we offer one of the largest ranges of primary antibodies with trial size options available.

The Antibody Validation Project works like this.
1. Order your trial size antibody online.
2. Explore its suitability.
3. Return your results by posting them on the product page.
4. Receive a sample refund.

Find out more here.